The drug is delivered as an oral once-daily capsule, capable of restoring mitochondrial quality control in injured kidney cells. “The divestment of MTX652 frees up resources for Mission to accelerate the development of MTX325, its clinical-stage USP30 inhibitor for Parkinson’s disease.” Now, the MTX652’s mechanism of action underpins MTX325 - Mission’s lead candidate for the treatment of Parkinson’s disease. “Furthermore, it is now well known that mitochondrial dysfunction is strongly linked to the pathophysiology underlying Parkinson’s disease. Consequently, Mission Therapeutics believes MTX325 – a first-in-class, highly potent, orally bioavailable brain penetrant – offers the potential of being an effective disease-modifying treatment for Parkinson’s disease.”